Hall Bradley, Padussis James, Foster Jason M
Division of General Surgery, University of Nebraska Medical Center, 984030 Nebraska Medical Center, Omaha, NE 68198-4030, USA.
Division of Surgical Oncology, University of Nebraska Medical Center, 984030 Nebraska Medical Center, Omaha, NE 68198-4030, USA.
Surg Clin North Am. 2017 Jun;97(3):671-682. doi: 10.1016/j.suc.2017.01.013.
Historically, patients with peritoneal carcinomatosis secondary to colorectal cancer have a poor overall prognosis. Recent data support the use of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS + HIPEC) to specifically address the peritoneal disease. Retrospective studies on CRS + HIPEC have been promising, showing significant improvements in OS compared with systemic chemotherapy alone. However, CRS + HIPEC carries morbidity similar to other advance oncology procedures such as liver resection and pancreatoduonectomy. It is hoped that ongoing clinical trials will clarify its role in the treatment of patients with peritoneal metastatic colorectal cancer.
从历史上看，结直肠癌继发腹膜癌的患者总体预后较差。近期数据支持采用细胞减灭术和热灌注化疗（CRS + HIPEC）来专门治疗腹膜疾病。关于CRS + HIPEC的回顾性研究前景良好，与单纯全身化疗相比，总生存期有显著改善。然而，CRS + HIPEC的发病率与肝切除和胰十二指肠切除术等其他晚期肿瘤手术相似。希望正在进行的临床试验将阐明其在治疗腹膜转移性结直肠癌患者中的作用。
